Form 4: Syndax Pharmaceuticals CEO Michael Metzger Reports Stock Sale

Syndax Pharmaceuticals CEO Michael Metzger reports the sale of 7,814 shares of common stock at an average price of $15.0453, while also exercising options to acquire the same number of shares.

Summary

• Michael Metzger, CEO of Syndax Pharmaceuticals, reported a transaction involving the company's common stock on March 4, 2025.
• Metzger exercised stock options to acquire 7,814 shares at a price of $7.20 per share.
• Simultaneously, Metzger sold 7,814 shares at an average price of $15.0453 per share, with prices ranging from $15.00 to $15.27.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Metzger directly owns 300,121 shares of Syndax Pharmaceuticals.
• Metzger also holds 1,321,245 vested and immediately exercisable stock options, and 805,428 unvested stock options.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to exercise stock options and sell shares, often under pre-arranged trading plans like Rule 10b5-1, to manage their personal finances.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a significant component.
• Rule 10b5-1 plans are a standard practice among corporate executives to avoid accusations of insider trading.
• The reported transactions are typical for executives in publicly traded companies.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates